慢性淋巴性白血病市场:KOL的洞察

本报告提供全球慢性淋巴性白血病市场相关调查，市场概要，以及已上市治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

Breton型蛋白酪氨酸激梅(BTK)抑制剂/分解剂

• 已通过核准BTK抑制剂(46)
  • Ibruvica（依鲁替尼、艾伯维/强生）
  • Calabrutinib（阿斯特捷利康）
  • Brukinsa（zanubrutinib、百济神州）
  • Japirka（piltobrutinib，礼来公司）
• 开发平台(管线)BTK抑制剂及分解剂
  • nemutaburuchinibu(Merck & Co.)
  • NX-5948，NX-2127(Nurix Therapeutics)及BGB-16673(BeiGene)

Bcl-2抑制剂

• 已通过核准治疗方法
  • Venclexta/Venclyxt（Venetoclax、艾伯维/罗氏）
• 开发平台(管线)疗法
  • Sonrotoclax（BGB-11417；百济神州）和 Risaftoclax（亚盛医药）

CAR T细胞疗法

• 开发平台(管线)医药品
  • Brayange（Lysocabtagen Malaleucel、百时美施贵宝）
  • MB-106(Mustang Bio)

双特异性抗体

• 开发平台(管线)医药品
  • Epkinley/Tepkinley（epcolitamab、AbbVie/Genmab）和 Colombi（grofitamab、罗氏）

今后的治疗趋势

• 主要的洞察摘要

附录

How do the experts see the potential for fixed-duration combination treatments playing out in first-line CLL therapy? Why do KOLs say AstraZeneca's Calquence + AbbVie/Roche's Venclexta combination is important? What opportunities lie ahead for BeiGene's Brukinsa? How do KOLs assess the potential of BTK degraders such as Nurix's NX-5948 and BeiGene's BGB-16673? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (11)

Current and future treatment algorithm

Research objectives (2)

Bruton's tyrosine kinase (BTK) inhibitors/degraders (66)

• Approved BTK inhibitors (46)
  • Imbruvica (ibrutinib; AbbVie/J&J) (11)
  • Calquence (acalabrutinib; AstraZeneca) (11)
  • Brukinsa (zanubrutinib; BeiGene) (9)
  • Jaypirca (pirtobrutinib; Lilly) (15)
• Pipeline BTK inhibitors and degraders (20)
  • Nemtabrutinib (Merck & Co.) (10)
  • NX-5948, NX-2127 (Nurix Therapeutics) & BGB-16673 (BeiGene) (10)

Bcl-2 inhibitors (19)

• Approved therapies (10)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (10)
• Pipeline therapies (9)
  • Sonrotoclax (BGB-11417; BeiGene) and lisaftoclax (Ascentage Pharma) (9)

CAR T-cell therapies (16)

• Pipeline drugs (16)
  • Breyanzi (lisocabtagene maraleucel; Bristol Myers Squibb) (11)
  • MB-106 (Mustang Bio) (5)

Bispecific antibodies (8)

• Pipeline drugs (8)
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab) and Columvi (glofitamab; Roche) (8)

Future treatment trends (5)

• Key insights summary (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)